Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications. (August 2022)

• Record Type: Journal Article
• Authors: Sher, Gulab; Salman, Nadia Aziz; Khan, Abdul Q.; Prabhu, Kirti S.; Raza, Afsheen; Kulinski, Michal; Dermime, Said; Haris, Mohammad; Junejo, Kulsoom; Uddin, Shahab
• Is Part Of: Seminars in cancer biology. Volume 83(2022)
• Page Start: 152
• Page End: 165
• Publication Date: 2022-08
• Subjects: MeCP2 Methyl-CpG-binding protein 2 -- H3 Histone 3 -- H4 Histone 4 -- TNBC Triple negative breast cancer -- ERα Estrogen receptor α -- PTEN Phosphatase and tensin homolog -- ERβ Estrogen receptor beta -- CAF Cancer-associated fibroblasts -- MMPs Matrix metallopeptidases -- TGF-β Transforming growth factor-β -- KMT2D Lysine methyltransferase 2D -- HDAC Histone deacetylases -- KDM7A Lysine demethylase 7A -- BCSCs Breast cancer stem cells -- ctDNA Cell-free tumor DNA -- LN Lymph node; Epigenetics -- Breast cancer -- DNA methylation -- Epigenetic drugs -- Biomarkers; Cancer -- Periodicals; Neoplasms -- Periodicals; Review Literature; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.semcancer.2020.08.009
• Languages: English
• ISSNs: 1044-579X

Abstract

Abstract: The global burden of breast cancer (BC) is increasing significantly. This trend is caused by several factors such as late diagnosis, limited treatment options for certain BC subtypes, drug resistance which all lead to poor clinical outcomes. Recent research has reported the role of epigenetic alterations in the mechanism of BC pathogenesis and its hallmarks include drug resistance and stemness features. The understanding of these modifications and their significance in the management of BC carcinogenesis is challenging and requires further attention. Nevertheless, it promises to provide novel insight needed for utilizing these alterations as potential diagnostic, prognostic markers, predict treatment efficacy, as well as therapeutic agents. This highlights the importance of continuing research development to further advance the existing knowledge on epigenetics and BC carcinogenesis to overcome the current challenges. Hence, this review aims to shed light and discuss the current state of epigenetics research in the diagnosis and management of BC.